Лечение рак-ассоциированного тромбоза: от рекомендаций к реальной клинической практике
- Авторы: Сомонова О.В.1, Елизарова А.Л.1, Блиндарь В.Н.1, Добровольская М.Б.1, Нестерова Ю.А.1, Борисенко Н.Н.1, Корнюшенко У.А.1, Давыдова Т.В.1
-
Учреждения:
- ФГБУ «НМИЦ онкологии им. Н.Н.Блохина»
- Выпуск: Том 21, № 1 (2019)
- Страницы: 60-65
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/33533
- DOI: https://doi.org/10.26442/18151434.2019.1.190247
- ID: 33533
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
Оксана Васильевна Сомонова
ФГБУ «НМИЦ онкологии им. Н.Н.Блохина»
Email: somonova@mail.ru
д-р мед. наук, вед. науч. сотр. 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Анна Львовна Елизарова
ФГБУ «НМИЦ онкологии им. Н.Н.Блохина»канд. биол. наук, ст. науч. сотр. 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Валентина Николаевна Блиндарь
ФГБУ «НМИЦ онкологии им. Н.Н.Блохина»д-р биол. наук, вед. науч. сотр 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Марина Борисовна Добровольская
ФГБУ «НМИЦ онкологии им. Н.Н.Блохина»канд. биол. наук, науч. сотр. 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Юлия Александровна Нестерова
ФГБУ «НМИЦ онкологии им. Н.Н.Блохина»мл. науч. сотр. 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Наталья Николаевна Борисенко
ФГБУ «НМИЦ онкологии им. Н.Н.Блохина»науч. сотр. 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Устин Александрович Корнюшенко
ФГБУ «НМИЦ онкологии им. Н.Н.Блохина»мл. науч. сотр. 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Татьяна Владимировна Давыдова
ФГБУ «НМИЦ онкологии им. Н.Н.Блохина»зав. лаб. клинико-лиагностической 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Список литературы
- Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost 2011; 9 (Suppl. 1): 316-24. doi: 10.1111/j.1538-7836.2011.04346.x
- Barsam S.J, Patel R, Arya. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. Br J Haematol 2013; 161 (Iss. 6): 764-77. doi: 10.1111/bjh.12314
- Wun T, White R.H. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haemotol 2009; 22 (1): 9-23. DOI: 0.1016/j.beha.2008.12.001
- Shaib W, Deng Y, Zilterman D et al. Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res 2010; 30 (10): 4261-4.
- Kakkar A.K, Haas S, Walsh D et al. Prevention of perioperative venous thromboembolism: outcome after cancer and non-cancer surgery (abstract). Thromb Haemost 2001; 86 (Suppl.): 0c1732. doi: 10.5144/0256-4947.2015.95
- Ogren M, Bergqvist D, Wahlander K et al. Trousseaus syndrome - what is the evidence? A population - based autopsy study. Thromb Haemost 2006; 95: 541-5. doi: 10.1160/TH05-10-0694
- Liebman H.A. Cancer prognosis in patients with venous thromboembolism (VTE) and patients with clinical and laboratory biomarkers predictive of VTE risk. Thromb Res; 2018; 164 (Suppl. 1): S19-22. doi: 10.1016/j.thromres.2018.01.040.
- Sorensen H.T, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50. doi: 10.1056/NEJM200012213432504
- Robin P, Carrier M. Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. Thromb Res 2018; 164 (Suppl. 1); S7-S11. doi: 10.1016/j.thromres.2017.12.024
- Magnus N, D’Asti E, Meehan B et al. Oncogenes and the coagulation system - forses that modulate dormant and aggressive states in cancer. Thromb Res 2014; 133 (Suppl. 2): S1-S9. https://doi.org/ 10.1016/S0049-3848(14)50001-1
- Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thromb Res 2018; 164 (Suppl. 1): S54-S61. doi: 10.1016/j.thromres.2018.01.017
- Cedervall J, Hamidi A, Olsson A-K. Platelets, NETs and cancer. Thromb Res 2018; 164 (Suppl. 1): S48-S52. doi: 10.1016/j.thromres.2018.01.049
- Nazari P.M.S, Riedy J, Pabinger I, Cihan Ay. The role of pododlanin in cancer-associated thrombosis. Thromb Res 2018; 164 (Suppl. 1): S34-S39. doi: 10.1016/j.thromres.2018.01.020
- Ten C.H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb 2007; 36: 122-30. doi: 10.1159/000175150
- Agnelii G, Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thromb Res 2010; 125 (Suppl. 2): S17-S20. doi: 10.1016/S0049-3848(10)70007-4
- Сомонова О.В. Диагностика нарушений гемостаза и принципы их коррекции при тромботических осложнениях в онкологии. Дис. … д-ра мед. наук. М., 2008.
- Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015; 9 (4; Вып. 2): 2-52.
- Franchini M, Bonfanti C, Lippi G. Cancer-associated thrombosis: investigating the role of new oral anticoagulants. Thromb Res 2015; 135 (5): 777-81. doi: 10.1016/j.thromres.2015.02.024
- Mandala M, Tondini C. Adjuvant therapy in breast cancer and venous thromboembolism. Thromb Res 2012; 130: S66-S70. doi: 10.1634/theoncologist.2012-0261
- Levine M.N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997; 78: 133-6.
- Goodnough L, Saito A, Manni A. Increased incidence of thromboembolism in stage IV breast cancer patients treated with five-drug chemotherapy regimen: a study of 150 patients. Cancer 1984; 78: 133-6. doi: 10.4061/2011/394740
- Otten H.M, Mathijssen J, Ten CH et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Inter Med 2004; 164: P190-4. doi: 10.1001/archinte.164.2.190
- Kearon C, Akl E.A, Ornelas J et al. Antithrombotic therapy for VTE disease. Chest 2016; 149 (2): 315-52. doi: 10.1016/j.chest.2 015.11.026
- Watson H.G, Keeling D.M, Laffan M et al. On behalf of British Committee for Standarts in Haemotology. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol 2015; 170 (Issue 5): 640-8. doi: 10.1111/bjh.13556
- Lee A.Y, Levine M.N, Baker M.D et al. Low-Molecular-Weight Heparin versus a Coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53. doi: 10.1056/NEJMoa025313
- Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: a review. Thromb Res 2018; 164 (Suppl. 1): S172-S177. doi: 10.1016/j.thromres.2017.12.019
- Khorana A., Yannicelli D, McGrae K.R et al. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res 2016; 14: 51-3. doi: 10.1016/j.thromres.2016.07.013
- Weitz J еt al. Clinical characteristics and initial treatment of patients with CAT. Results from Garfield VTE registry. Poster PB 460 presented at ISTH 2017.
- Prints M.H, Lensing A.W, Bauersachs R et al. Oral rivaroxaban versus standart therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21-31. https://doi.org/ 10.1186/1477-9560-11-21
- Prints M.H, Lensing A.W.A, Brighton T.A et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomized controlled trials. Lancet Haematol 2014; 1: e37-e46. doi: 10.1016/S2352-3026(14)70018-3
- Büller H.R, Prins M.H, Lensin A.W et al. Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97. DOI: 0.1056/NEJMoa1113572
- Van der Hulle T, den Exter P.L, Kooiman J et al. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 2014; 12 (7): 1116-20. doi: 10.1111/jth.12605
- Khorana A.A, McCrae K, MilentiJevic D et al. VTE recurrence and safety of anticoagulants among patients with cancer treated for venous thromboembolism. Blood 2017; 130: 4631.
- McBane R.D et al. presented at ACC 2016, abstract 1243M-05. doi: 10.7899/JCE-13-14
- Khorana A.A et al. presented at ASH 2017, abstract 4631.
- Ageno W, Mantovany L.G, Haas S et al. Subgroup analysis of patients with cancer in XALIA: a noninterventional study of rivaroxaban versus standard anticoagulation for VTE. TH Open 2017; 1 (1e): e33-e42. https://doi.org/.10.1055/s-0037-1603924
- Young A.M, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SEL ECT-D). J Clin Oncol 2018; 36 (20): 2017-23. doi: 10.1200/JCO.2018.78.8034
- Khorana A.A, Noble S, Lee A.Y et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance fr om the SSC of the ISTH. J Thromb Haemost 2018; 16: 1891-4. doi: 10.1111/jth.14219
- Streiff M.B, Holmstron B, Angelini D et al. NCCN Guidelines Insights. Cancer-associated venous thromboembolic disease, version 2.2018. Featured updates to the NCCN Guidelines. J. of the National Comprehensive cancer network. 2018; 16(11): 1289-303. doi: 10.6004/jnccn.2018.0084